Through two separate grants, Dr. Slingluff is exploring two strategies to make immunotherapy even more effective for patients.
Through his CLIP Grant, he aims to better understand how certain genes impact T cell infiltration into tumors as well as characterize other factors that modulate the expression of these genes and determine which barrier molecules actually interfere with immune cell infiltration into melanoma tumors. This could help identify new mechanisms responsible for preventing immune responses against tumors and may have translational applications that extend to treatment-related decision making in the clinic.”
Through his Clinical Team Grant, Dr. Slingluff, along with Jamal Zweit, Ph.D., is working on both antibody-based and vaccine-based strategies to target SAS1B, a marker highly expressed on the surface of tumor cells in uterine, pancreatic, and renal cancers.
Projects and Grants
Barrier Molecules and Their Impact on T cell Infiltration in Melanoma
University of Virginia Health System | Melanoma | 2017
Retention integrins: induction and function on cancer-reactive T lymphocytes
University of Virginia Health System | Lung Cancer, Melanoma | 2015
Immunotherapeutic targeting cell surface neoantigen SAS1B
University of Virginia Health System | Kidney Cancer, Pancreatic Cancer | 2015
Let's spread the word about Immunotherapy! Click to share this page with your community.